Hospital
Universal Health Services of Rancho Springs INC
Universal Health Services of Rancho Springs INC was paid $61.95M by Medicaid between Jan 2018 and Dec 2024, across 292 billing codes. Its largest line is 0450, Emergency room services — 14% of everything it billed.
33Billing provider infoUNIVERSAL HEALTH SERVICES OF RANCHO SPRINGS INC
MURRIETA, CA 92562
MURRIETA, CA 92562
33aNPI1245221050assigned 11/01/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$61.95M
24GClaims1,808,996
24DCodes billed292
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#48 of 410
Median peer was paid$6.90M
This provider vs. median9.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 272,112 | $7.42M | |
| 2019 | 307,351 | $8.85M | |
| 2020 | 212,684 | $6.70M | |
| 2021 | 235,980 | $8.07M | |
| 2022 | 259,439 | $9.51M | |
| 2023 | 275,684 | $10.68M | |
| 2024incomplete | 245,746 | $10.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 14% | 160,306 | 139,682 | $8.72M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.7% | 90,972 | 80,903 | $5.42M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.2% | 13,657 | 13,164 | $4.44M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.8% | 33,050 | 30,543 | $2.99M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.7% | 4,428 | 4,339 | $2.31M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 19,210 | 18,428 | $2.21M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.2% | 12,201 | 11,733 | $2.01M |
| 93975 | 3.1% | 5,977 | 5,756 | $1.93M | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 47,202 | 42,554 | $1.44M |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.3% | 23,824 | 21,728 | $1.41M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.2% | 32,657 | 29,964 | $1.35M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.8% | 5,833 | 5,596 | $1.13M |
280 more codes
| 72125 | Computed tomography, cervical spine; without contrast material | 1.7% | 6,739 | $1.08M |
| 80053 | Comprehensive metabolic panel | 1.7% | 86,487 | $1.05M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 12,957 | $1.05M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 9,484 | $1.02M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.5% | 3,459 | $949K |
| L8699 | Prosthetic implant, not otherwise specified | 1.5% | 531 | $939K |
| 99285 | Emergency room visit (most serious) | 1.3% | 6,672 | $810K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 88,806 | $754K |
| 99499 | 1.2% | 8,675 | $751K | |
| 71045 | Radiologic examination, chest; single view | 1.1% | 41,414 | $706K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.1% | 9,010 | $653K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 17,630 | $593K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,343 | $564K |
| 99284 | Emergency room visit (serious) | <1% | 5,655 | $499K |
| 93971 | <1% | 3,545 | $483K | |
| 76801 | <1% | 5,531 | $476K | |
| 70496 | <1% | 1,652 | $424K | |
| 84484 | <1% | 37,317 | $418K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,879 | $371K |
| 70498 | <1% | 1,726 | $367K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,227 | $356K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,864 | $343K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,542 | $333K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,029 | $327K |
| 70486 | <1% | 2,090 | $285K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,741 | $284K |
| 83690 | <1% | 36,310 | $281K | |
| 93970 | <1% | 1,115 | $278K | |
| Z7502 | <1% | 7,309 | $276K | |
| 72131 | <1% | 1,746 | $271K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,296 | $260K |
| 83880 | <1% | 7,827 | $255K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 674 | $235K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,915 | $229K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 18,715 | $224K |
| 59025 | Fetal non-stress test | <1% | 10,397 | $222K |
| J3490 | Unclassified drugs | <1% | 82,358 | $209K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,461 | $198K |
| 0762 | <1% | 961 | $195K | |
| 81003 | <1% | 70,226 | $194K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,002 | $182K |
| 81025 | <1% | 33,347 | $173K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,879 | $173K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,743 | $170K |
| 99070 | <1% | 91,721 | $150K | |
| 84702 | <1% | 8,519 | $149K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,311 | $145K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,717 | $144K |
| 73630 | <1% | 4,990 | $143K | |
| 74174 | <1% | 365 | $139K | |
| 73610 | <1% | 4,516 | $137K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,247 | $134K |
| 73130 | <1% | 4,387 | $133K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,531 | $131K |
| 85610 | <1% | 30,595 | $130K | |
| 85730 | <1% | 20,009 | $126K | |
| 83735 | <1% | 18,151 | $126K | |
| 84703 | <1% | 14,048 | $121K | |
| 90715 | <1% | 3,512 | $120K | |
| 72100 | <1% | 3,424 | $116K | |
| 85027 | <1% | 16,455 | $116K | |
| 73030 | <1% | 3,871 | $113K | |
| 87040 | <1% | 9,133 | $103K | |
| 73564 | <1% | 3,067 | $99K | |
| 0710 | <1% | 2,002 | $94K | |
| 73110 | <1% | 3,050 | $94K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,454 | $93K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,934 | $92K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,441 | $88K |
| 84439 | <1% | 8,792 | $86K | |
| 83605 | <1% | 7,480 | $82K | |
| 74018 | <1% | 2,995 | $81K | |
| 81001 | <1% | 22,686 | $81K | |
| 76870 | <1% | 1,247 | $81K | |
| 74022 | <1% | 1,698 | $75K | |
| 73080 | <1% | 2,339 | $72K | |
| 99221 | <1% | 385 | $72K | |
| 71250 | <1% | 524 | $71K | |
| 85379 | <1% | 5,993 | $69K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,736 | $65K |
| 72040 | <1% | 2,185 | $65K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 31,166 | $65K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14,228 | $62K |
| 73562 | <1% | 2,206 | $61K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,598 | $59K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 249 | $59K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 344 | $58K |
| 73590 | <1% | 2,380 | $58K | |
| 0353U | <1% | 757 | $58K | |
| 73090 | <1% | 2,272 | $56K | |
| 94644 | <1% | 1,710 | $55K | |
| 72128 | <1% | 364 | $54K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 783 | $54K |
| 87186 | <1% | 5,750 | $53K | |
| 87077 | <1% | 6,027 | $50K | |
| 12011 | <1% | 1,576 | $50K | |
| 73502 | <1% | 1,214 | $48K | |
| 12001 | <1% | 1,942 | $46K | |
| 87276 | <1% | 4,382 | $45K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 23,827 | $45K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 673 | $43K |
| 0250 | <1% | 7,914 | $42K | |
| 70491 | <1% | 191 | $41K | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 388 | $41K |
| 76775 | <1% | 674 | $40K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 502 | $40K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,153 | $40K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,740 | $36K |
| 87631 | <1% | 503 | $36K | |
| 72072 | <1% | 990 | $35K | |
| 82962 | <1% | 9,062 | $34K | |
| 74019 | <1% | 970 | $34K | |
| 86901 | <1% | 9,446 | $34K | |
| 72170 | <1% | 1,348 | $32K | |
| 87275 | <1% | 4,387 | $32K | |
| 82550 | <1% | 4,517 | $32K | |
| 71101 | <1% | 871 | $31K | |
| 86900 | <1% | 9,459 | $31K | |
| 87070 | <1% | 2,962 | $29K | |
| 86850 | <1% | 4,889 | $29K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,017 | $26K |
| 82803 | <1% | 1,563 | $25K | |
| G0378 | Hospital observation service, per hour | <1% | 326 | $25K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 533 | $25K |
| 86141 | <1% | 1,698 | $24K | |
| 0272 | <1% | 194 | $24K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,538 | $24K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,938 | $24K |
| 96367 | <1% | 441 | $23K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,595 | $22K |
| 0510 | <1% | 857 | $22K | |
| 29125 | <1% | 1,754 | $21K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,322 | $21K |
| 86923 | <1% | 240 | $20K | |
| 10060 | <1% | 784 | $19K | |
| 73140 | <1% | 920 | $19K | |
| 86140 | <1% | 3,185 | $19K | |
| 73552 | <1% | 563 | $18K | |
| 0270 | <1% | 7,449 | $18K | |
| 0360 | <1% | 190 | $17K | |
| 31720 | <1% | 653 | $16K | |
| 12002 | <1% | 594 | $16K | |
| 51701 | <1% | 883 | $16K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 479 | $15K |
| 87430 | <1% | 1,262 | $14K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,844 | $14K |
| 82553 | <1% | 1,143 | $13K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 477 | $13K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,746 | $13K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 417 | $12K |
| 82010 | <1% | 1,464 | $12K | |
| Z7610 | <1% | 1,218 | $12K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 36 | $12K |
| 93976 | <1% | 45 | $12K | |
| 29515 | <1% | 861 | $11K | |
| 87210 | <1% | 2,168 | $11K | |
| 99199 | Unlisted special service, procedure or report | <1% | 230 | $11K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 146 | $10K |
| 87205 | <1% | 2,362 | $10K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 5,013 | $10K |
| 73060 | <1% | 412 | $10K | |
| 87641 | <1% | 266 | $10K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 151 | $10K |
| 96376 | <1% | 910 | $9K | |
| 86677 | <1% | 503 | $9K | |
| 71010 | <1% | 377 | $9K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 425 | $9K |
| 84100 | <1% | 1,794 | $9K | |
| 87081 | <1% | 1,102 | $9K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,195 | $9K |
| 82375 | <1% | 556 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,399 | $8K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,554 | $7K |
| 71020 | <1% | 176 | $7K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,888 | $7K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,780 | $7K |
| 36000 | <1% | 963 | $7K | |
| 85652 | <1% | 2,207 | $7K | |
| 84550 | <1% | 1,110 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,548 | $6K |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 120 | $6K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 71 | $5K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 293 | $5K |
| 82810 | <1% | 513 | $5K | |
| 87420 | <1% | 765 | $5K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 323 | $5K |
| 83050 | <1% | 558 | $5K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 55 | $5K |
| 86308 | <1% | 794 | $5K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 914 | $5K |
| 80061 | Lipid panel | <1% | 464 | $4K |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 430 | $4K |
| 72141 | <1% | 12 | $4K | |
| 70360 | <1% | 213 | $4K | |
| 82140 | <1% | 266 | $4K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 300 | $4K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 578 | $3K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 24 | $3K |
| 74021 | <1% | 89 | $3K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,075 | $3K |
| 99217 | <1% | 110 | $3K | |
| 97597 | <1% | 69 | $3K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,751 | $3K |
| 85384 | <1% | 279 | $3K | |
| 29105 | <1% | 217 | $3K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 14 | $3K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 743 | $3K |
| 88307 | <1% | 65 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 490 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 309 | $2K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,031 | $2K |
| 82570 | <1% | 349 | $2K | |
| 84132 | <1% | 153 | $2K | |
| 84145 | <1% | 89 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 994 | $2K |
| 88304 | <1% | 141 | $2K | |
| 83986 | <1% | 375 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,748 | $2K |
| 88342 | <1% | 54 | $2K | |
| 82150 | <1% | 202 | $2K | |
| 51702 | <1% | 124 | $2K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 217 | $1K |
| 87486 | <1% | 36 | $1K | |
| 87581 | <1% | 36 | $1K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 256 | $1K |
| 84156 | <1% | 329 | $1K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 107 | $1K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 65 | $1K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 537 | $1K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 497 | $1K |
| 73000 | <1% | 51 | $1K | |
| 82272 | <1% | 563 | $1K | |
| 72070 | <1% | 44 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 695 | $1K |
| 82731 | <1% | 12 | $860.82 | |
| 87320 | <1% | 58 | $856.52 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 299 | $836.74 |
| 74000 | <1% | 31 | $824.91 | |
| 76010 | <1% | 26 | $723.52 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 73 | $692.02 |
| 87045 | <1% | 67 | $656.27 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 84 | $637.13 |
| 82728 | <1% | 44 | $629.53 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 542 | $593.48 |
| 36430 | <1% | 30 | $515.49 | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 31 | $513.75 |
| 83721 | <1% | 54 | $505.46 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 62 | $462.55 |
| L3999 | Upper limb orthosis, not otherwise specified | <1% | 157 | $435.66 |
| 86703 | <1% | 26 | $433.30 | |
| Q3014 | Telehealth originating site facility fee | <1% | 12 | $424.48 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 14 | $396.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 47 | $374.86 |
| 81002 | <1% | 120 | $373.17 | |
| A9270 | Non-covered item or service | <1% | 3,366 | $366.05 |
| 84450 | <1% | 61 | $357.84 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 162 | $330.48 |
| 80076 | <1% | 41 | $321.79 | |
| 83615 | <1% | 42 | $314.30 | |
| 86780 | <1% | 25 | $286.18 | |
| 87147 | <1% | 52 | $284.06 | |
| 84460 | <1% | 46 | $272.63 | |
| 73660 | <1% | 13 | $222.86 | |
| 82248 | <1% | 28 | $218.08 | |
| 82565 | <1% | 29 | $179.17 | |
| 85007 | <1% | 45 | $143.53 | |
| 90686 | <1% | 14 | $137.67 | |
| 84520 | <1% | 28 | $129.33 | |
| 82247 | <1% | 12 | $116.53 | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | <1% | 194 | $99.21 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 58 | $83.95 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 12 | $77.12 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 199 | $60.87 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 21 | $50.00 |
| 82040 | <1% | 12 | $47.79 | |
| 85014 | <1% | 14 | $42.45 | |
| 85018 | <1% | 14 | $42.45 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 58 | $22.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 29 | $17.10 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 44 | $7.42 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFILTON, STEVE (CFO, SENIOR VP)
| Provider | Location | Paid |
|---|---|---|
| District Hospital Partners L P | Washington, DC | $136.25M |
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Lancaster Hospital Corporation | Palmdale, CA | $108.63M |
| Doctors Hospital of Laredo | Laredo, TX | $52.31M |
| Valley Hospital Medical Center | Las Vegas, NV | $47.03M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Spring Valley Medical Center | Las Vegas, NV | $33.58M |
| Aiken Regional Medical Centers LLC | Aiken, SC | $31.51M |
| Summerlin Hospital Medical Center L L C | Las Vegas, NV | $30.26M |
| Manatee Memorial Hospital L P | Bradenton, FL | $22.33M |
| Desert Springs Hospital | Las Vegas, NV | $22.29M |
| Fort Duncan Medical Center LP | Eagle Pass, TX | $15.80M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
| Friends Behavioral Health System, LP | Philadelphia, PA | $9.55M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.